No Data
Hualan Co., Ltd.: 2024 Annual Results Forecast
Hualan Co., Ltd. (301093.SZ) plans to invest in the establishment of a subsidiary in South Korea.
Hualan Co., Ltd. (301093.SZ) announced that, based on the needs of the company's Global Strategy development and actual Operation conditions, the company plans to...
Hualan Co., Ltd. (301093.SZ): Termination of the 2022 restricted Stocks incentive plan.
On December 27, Gelonghui announced that Hualan Co., Ltd. (301093.SZ) held the thirty-first meeting of the fifth Board of Directors and the twenty-eighth meeting of the fifth Supervisory Board on December 27, 2024. It reviewed and approved the "Proposal on Terminating the Implementation of the 2022 Restricted Stocks Incentive Plan and the Buyback, Cancellation, and Invalidity of Restricted Stocks." Given that there have been significant changes in both the internal and external operational environments compared to when the incentive plan was formulated, there is considerable uncertainty in meeting the subsequent performance assessment targets set by this incentive plan, and continuing to implement this incentive plan is unlikely to achieve the expected incentive objectives and effects.
Hualan Co., Ltd. (301093.SZ) intends to postpone the "Research and Development Center Construction Project" to June 30, 2025.
On December 27, 2023, Gelonghui reported that Hualan Co., Ltd. (301093.SZ) announced that based on the current progress and actual situation of the fundraising investment projects, the company decided to postpone the "Research and Development Center Construction Project", extending the date for the project to reach the designated usable state from December 31, 2024, to June 30, 2025, without changing the implementation主体、implementation method, use of raised funds, and investment scale.
Hualan Co., Ltd.: Report for the third quarter of 2024
While Institutions Invested in Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SZSE:301093) Benefited From Last Week's 19% Gain, Retail Investors Stood to Gain the Most
The Returns On Capital At Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093) Don't Inspire Confidence
